↓ Skip to main content

American Association for Cancer Research

Article Metrics

Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses

Overview of attention for article published in Molecular Cancer Therapeutics, December 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
6 news outlets
twitter
1 tweeter

Readers on

mendeley
8 Mendeley
Title
Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses
Published in
Molecular Cancer Therapeutics, December 2020
DOI 10.1158/1535-7163.mct-20-0457
Pubmed ID
Authors

Stella A. Martomo, Dan Lu, Zhanna Polonskaya, Xenia Luna, Zhikai Zhang, Sam Feldstein, Radovan Lumban-Tobing, Danielle K. Almstead, Faical Miyara, Jeegar Patel

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 50%
Student > Doctoral Student 2 25%
Other 1 13%
Student > Master 1 13%
Readers by discipline Count As %
Agricultural and Biological Sciences 3 38%
Immunology and Microbiology 2 25%
Veterinary Science and Veterinary Medicine 1 13%
Biochemistry, Genetics and Molecular Biology 1 13%
Medicine and Dentistry 1 13%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 42. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2021.
All research outputs
#580,227
of 16,898,023 outputs
Outputs from Molecular Cancer Therapeutics
#65
of 3,145 outputs
Outputs of similar age
#8,966
of 176,023 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#1
of 18 outputs
Altmetric has tracked 16,898,023 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,145 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,023 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.